Dr. Gregor Adams Joins MI Bioresearch as Director of Scientific Development

November 29, 2018

MI Bioresearch is pleased to announce that Dr. Gregor Adams has joined us as Director of Scientific Development. Dr. Adams received his Ph.D. from Imperial College School of Medicine in London, United Kingdom where his thesis focused on the development of a gene therapy for HIV-1 infection. He then continued his research career in cell therapy in the laboratory of Dr. David T. Scadden at Massachusetts General Hospital, Harvard Medical School with an emphasis on the interaction of hematopoietic stem cells with their microenvironmental niche. As a faculty member of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of Southern California, Dr. Adams’ research remained focused on the interactions of normal and malignant hematopoietic cells with their microenvironment. In 2015, he left academia to lead the in vivo pharmacology team at Kite Pharma. During his tenure at Kite, Dr. Adams’ responsibilities included overseeing preclinical in vivo studies for the development of all chimeric antigen receptor and engineered T cell receptor-based therapies in Kite’s pipeline.

At MI Bioresearch, Dr. Adams will interface directly with clients and potential clients to assure optimum translation of needs into MI Bioresearch studies. His extensive experience overseeing in vivo pharmacology aimed at bringing a variety of CAR-T and TCR therapies from preclinical efforts into clinical development will help propel MI Bioresearch and client efforts in these fields.

About MI Bioresearch

MI Bioresearch is a leading preclinical oncology and immuno-oncology contract research provider with extensive tumor model experience and advanced in vivo imaging, flow cytometry, and radiation dosing capabilities. Partner with our scientific team to get the best decision-enabling data out of every study and move your drug program forward. One Focus. One Purpose. Oncology Research.